Drug Trial Radar · NCT07536061
A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
May 12, 2026
Primary completion
Nov 30, 2027
Study completion Nov 30, 2027
Sponsor
- Lead sponsor
- Sarepta Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 21 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first-in-human, multi-center trial studying the effects of SRP-1005 in participants with Huntington's disease (HD).
Conditions
- Huntington's Disease
Interventions
SRP-1005Drug
Subcutaneous injection
PlaceboDrug
Subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with a Treatment-emergent Adverse Event (TEAE), Serious Adverse Event (SAE), and Adverse Event of Special Interest (AESI)Time frame: Baseline through Week 24
Locations
8 sites in 5 countries. Site status is shown where the registry gives one.
Westmead Hospital
Westmead, New South Wales, Australia · Recruiting
Royal Melbourne Hospital
Parkville, Victoria, Australia · Recruiting
New Zealand Brain Research Institute
Christchurch, New Zealand · Recruiting
Seoul National University Hospital
Seoul, South Korea · Recruiting
Siloah AG
Gümligen, Canton of Bern, Switzerland · Recruiting
University Hospital Birmingham
Birmingham, United Kingdom · Recruiting
University Hospital of Wales
Cardiff, United Kingdom · Recruiting
John Radcliffe Hospital
Oxford, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.